Gordon, K, RB Warren, AB Gottlieb, A Blauvelt, D Thaçi, Y Poulin, M Boehnlein, F Brock, C Arendt, and K Reich. “Durable Efficacy of Certolizumab Pegol Dosed at 400 Mg Every Two Weeks Over 128 Weeks in Patients With Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2, and CIMPACT)”. SKIN The Journal of Cutaneous Medicine 4, no. 6 (October 27, 2020): s81. Accessed January 24, 2021. https://jofskin.org/index.php/skin/article/view/1114.